SCHEMBL10986

SCHEMBL10986

COc1c(F)cc(Br)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TUBB1 Q9H4B7 5/20 0.39
MAPT P10636 3/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
DBH P09172 1/20 0.36
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodomethane SCHEMBL4667431 0.95 HSD17B10 (0.38) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL17875684 0.88 HSD17B10 (0.50) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL26927713 0.86 ALOX15 (0.47) CA2CA4TUBB1MAPTALOX15
SCHEMBL930657 0.86 KDM4E (0.40) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL31500460 0.86 ALOX15 (0.47) CA2CA4TUBB1MAPTALOX15
SCHEMBL24252805 0.84 HSD17B10 (0.35) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL2309487 0.84 POLB (0.38) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL15271622 0.84 ACLY (0.41) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL16596078 0.84 TDP1 (0.46) CA2CA4HSD17B10TUBB1MAPT
SCHEMBL31190021 0.84 POLB (0.38) CA2CA4HSD17B10TUBB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 EP disclosed
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 EP disclosed
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP disclosed
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 US disclosed
WO-2025085527-A1 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF THE CLEVELAND CLINIC FOUNDATION (US) 2025-04-24 WO disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US disclosed
WO-2024254539-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-11-14 US disclosed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-6645973-B1 Heterocyclic amines such as 1-carboxymethyl-4-(4-chlorophenyl) spiro(2H-1-benzopyran-2,4'-piperidine)hydrochloride used for therapy of nervous system disorders; Alzheimer's, Parkinson's and Huntington's disease AKZO NOBEL (NL) 2003-11-11 US disclosed
US-20030108684-A1 Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors CLARIANT INTERNATIONAL LTD. 2003-06-12 US disclosed
EP-1232160-A1 SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS Akzo Nobel N.V. (NL) 2002-08-21 EP disclosed
EP-1223209-A1 Fluorinated fluorenes and use thereof in liquid crystal mixtures CLARIANT INTERNATIONAL LTD. (CH) 2002-07-17 EP disclosed
EP-0637623-B1 Cyclic hydrocarbon derivative and liquid crystal composition containing the same DAINIPPON INK & CHEMICALS (JP) 2001-10-04 EP disclosed
WO-2001036423-A1 SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE) DERIVATES AS GLYCINE TRANSPORT INHIBITORS AKZO NOBEL N.V. (NL) 2001-05-25 WO disclosed
US-6110962-A FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 US disclosed
US-5536443-A DUTERIUM CONTAINING COMPOUNDS FOOR ELECTROOPTICAL APPARATUS DAINIPPON INK & CHEMICALS, INC. (JP) 1996-07-16 US disclosed
US-5474707-A Electrooptic display DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-12-12 US disclosed
EP-0637623-A1 Cyclic hydrocarbon derivative and liquid crystal composition containing the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108684-A1 Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors SCO2, CYP2F1, OGFOD1 CA2 1107/4885CA4 1561/4885HSD17B10 490/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 CA2 472/4885CA4 1110/4885HSD17B10 1838/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA2 3756/4885CA4 4807/4885HSD17B10 3265/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 CA2 1321/4885CA4 993/4885HSD17B10 163/4885
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE DDC, AADAT, TYR CA2 821/4885CA4 431/4885HSD17B10 1264/4885
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR CA2 722/4885CA4 1603/4885HSD17B10 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.